Advertisements

VistaGen Therapeutics Inc. (VTGN) Stock Quote

Detailed Quote for VistaGen Therapeutics Inc. (VTGN)
$ 0.85   -0.025 (-2.86%) Volume: 242.1k 4:00 PM EDT 25-Apr-2018
Today 5d 1m 3m 1y more
Last Price
0.85
Change $
0.025
Change %
2.86%
Tick
N/A
Bid
0.83
Bid Size
600
Ask
0.91
Ask Size
1,000
Open
0.88
High
0.88
Low
0.83
Prev Close
0.875
Last Trade
4:00
Volume
242.1k
52 Wk Hi
2.65000009
52 Wk Low
0.689999997
Market Cap
19.47m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
22,902,615
EPS (TTM)
-1.37
PE Ratio
N/A
Exchange
NCM
News and Media for VistaGen Therapeutics Inc. (VTGN)
Sector News | Topic News
News for VistaGen Therapeutics Inc. (VTGN)
Fri, Apr 20, 2018
12:55 PM Midday Gainers / Losers (04/20/2018) - SeekingAlpha
11:39 AM Vistagen down 11% on mixed esketamine data - SeekingAlpha
9:17 AM Premarket Losers as of 9:05 am (04/20/2018) - SeekingAlpha
Tue, Apr 10, 2018
8:30 AM VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101 - Marketwired
8:30 AM VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101 - Marketwired
Fri, Apr 06, 2018
11:18 AM Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study - SeekingAlpha
Thu, Apr 05, 2018
8:45 AM VistaGen Therapeutics initiates Phase 2 study of AV-101 for MDD - SeekingAlpha
8:00 AM VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder - Marketwired
8:00 AM VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder - Marketwired
Wed, Mar 21, 2018
1:49 PM Vistagen - Nanocap CNS Drug Chasing Ketamine Fame - SeekingAlpha
Mon, Mar 19, 2018
10:17 AM VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101 - Marketwired
10:17 AM VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101 - Marketwired
Fri, Mar 16, 2018
10:25 AM Key events next week - healthcare - SeekingAlpha
Fri, Mar 09, 2018
11:51 AM Your Daily Pharma Scoop: Progenics Rallies, Merck To Partner With Eisai, Teva Upsizes Debt Offering - SeekingAlpha
9:14 AM Premarket Losers as of 9:05 am (3/9/2018) - SeekingAlpha
Wed, Mar 07, 2018
10:01 AM VistaGen nabs U.S. patent covering lead candidate AV-101; shares up 3% - SeekingAlpha
9:00 AM VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101 - Marketwired
9:00 AM VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101 - Marketwired
Tue, Mar 06, 2018
9:11 AM Premarket Gainers as of 9:05 am (03/06/2018) - SeekingAlpha
Mon, Mar 05, 2018
9:02 AM VistaGen Therapeutics to Present at Oppenheimer's 28th Annual Healthcare Conference on March 21, 2018 - Marketwired
More News for VTGN >>

Tags for VistaGen Therapeutics Inc.

Research stocks or mutual funds related to VistaGen Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to VTGN. The keywords below have been associated to VTGN by either user submission or electronic means.